Pulse Biosciences reported a Q4 2025 non-GAAP net loss of $0.26 per share, outperforming consensus estimates of a $0.32 loss and narrowing its deficit from $0.17 per share in Q4 2024. Revenue performance details were not disclosed, but the reduction in loss underscores improved cost controls and operational execution.

The company confirmed that enrollment for its investigational device exemption (IDE) study will begin within the next one to two months and is projected to conclude by the end of 2026. Management is prioritizing this trial and exploring process enhancements to accelerate patient recruitment and data collection.

Vibrance remains in a limited release market development phase, with broader commercialization contingent on FDA therapeutic indications and reimbursement approvals. The post-market surveillance study for thyroid applications aims to enroll 100 patients within the next few months to strengthen the clinical data package.

Pulse Biosciences is actively pursuing FDA therapeutic clearances essential for revenue growth and expects to obtain reimbursement labels by 2027. Funding strategies include potential partnerships and distribution agreements to maintain financial flexibility through the approval and commercialization phases.